Moderna Inc. (NASDAQ: MRNA) announced it will present Phase 1/2 data on its investigational cancer therapy mRNA-4359 at the American ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE